Economic burden of multiple sclerosis in an Italian cohort of patients on disease-modifying therapy: analysis of disease cost and its components.

Autor: Ponzio M; Italian Multiple Sclerosis Foundation (FISM), Genoa, Italy. michela.ponzio@aism.it., Santoni L; Biogen Italia, Milan, Italy., Molina M; Biogen Italia, Milan, Italy., Tavazzi E; Multiple Sclerosis Research Center, IRCCS Mondino Foundation, Pavia, Italy., Bergamaschi R; Multiple Sclerosis Research Center, IRCCS Mondino Foundation, Pavia, Italy.
Jazyk: angličtina
Zdroj: Journal of neurology [J Neurol] 2024 Dec 12; Vol. 272 (1), pp. 50. Date of Electronic Publication: 2024 Dec 12.
DOI: 10.1007/s00415-024-12729-y
Abstrakt: In this observational cross-sectional study conducted in Italy, sociodemographic and disease data were collected from a multiple sclerosis (MS) population treated with disease-modifying therapies (DMTs). A prevalence-based cost-of-illness analysis was subsequently carried out. In total, 393 MS patients were enrolled, 65.9% female, average age of 45 ± 11.5 years. 94.9% had RRMS and EDSS median value of 1.5 (1.0, 2.0). The mean total cost per MS patient was estimated at €20,299.4 per year. Total costs of MS increase by disability level, varying from 16,812.0 (minor) to 20,407.0 (mild), 27,640.7 (moderate), and 44,404.0 (severe). DMT costs accounted for 62.5% of total costs, while productivity loss accounted for 22.0%. Indeed, besides having low quality of life decline and fatigue levels, most patients enrolled retained full working capacity while 31.3% had some productivity loss. The results obtained are in line with previous studies showing that as the disease progresses, the quality of life, fatigue and working capacity worsen alongside a rise in total MS costs for either the society or the healthcare service. Clinical relapses cause a significant cost increment. This cross-sectional study provides a representation of MS quality of life and MS cost in a cohort of Italian MS patients treated with DMT, among which the majority had RRMS. This cost-of-illness analysis can provide useful information for resource allocation and help estimate the savings that can be obtained by slowing the progression of the disease. It also constitutes a primary source of data useful for conducting a complete economic evaluation analysis, including cost-effectiveness and cost-utility analyses.
Competing Interests: Declarations. Conflict of interest: Ponzio M. has no conflicts of interest to declare; Santoni L. is an employee of and may hold stock in Biogen; Tavazzi E. received honoraria for speaking from Biogen Idec, Bristol-Meyers-Squibb; Molina M. is an employee of and may hold stock in Biogen; Bergamaschi R. received honoraria for speaking from Biogen, Merck Serono, Roche, Novartis, Celgene, Janssen, Sanofi Genzyme; research grants from Biogen, Merck Serono, Roche, Novartis, Sanofi Genzyme; congress and travel/accommodation expenses funded by Biogen, Merck Serono, Roche, Novartis, Sanofi Genzyme. Ethical approval: The study protocol was approved by the Ethical Committee of the San Matteo Hospital in Pavia (PR 20180042426; 06/06/2018) and was conducted in accordance with the rules of the Declaration of Helsinki and all applicable local law requirements and regulations concerning the privacy and security of personal information, including the General Data Protection Regulation (GDPR) (EU) 2016/679. An informed consent form was obtained from all patients enrolled in the study.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: